Researchers have identified two brain receptors that appear to regulate the clearance of amyloid beta, a protein that accumulates in the brains of individuals with Alzheimer’s disease. The discovery, announced February 17, 2026, by scientists at Karolinska Institutet in Sweden and the RIKEN Center for Brain Science in Japan, could pave the way for more affordable and accessible treatments for the debilitating neurodegenerative condition.
The study, published in the Journal of Alzheimer’s Disease, focused on the role of neprilysin, an enzyme responsible for breaking down amyloid beta. Researchers found that the activity of neprilysin declines with age and during the progression of Alzheimer’s disease. Their function revealed that two somatostatin receptors, SST1 and SST4, work in concert to control neprilysin levels specifically within the hippocampus, a brain region critical for memory formation.
Experiments conducted on genetically modified mice lacking both SST1 and SST4 receptors demonstrated a significant drop in neprilysin levels. This suggests a direct link between the receptors and the brain’s natural ability to clear amyloid beta. The findings build on existing research identifying the pathological deposition of amyloid-β plaques as a key characteristic of Alzheimer’s disease, a condition affecting millions worldwide and often misdiagnosed as a consequence of aging, according to a recent review published in Nature.
“These receptors are common drug targets,” said a spokesperson for Karolinska Institutet, indicating the potential for repurposing existing medications or developing new ones. The current standard of care often involves antibody-based treatments, which can be expensive and may have significant side effects. Stimulating the SST1 and SST4 receptors in mice led to increased neprilysin activity, reduced amyloid beta buildup, and improvements in memory-related behaviors.
The research also aligns with broader investigations into the interplay between amyloid-β and tau protein in the pathogenesis of Alzheimer’s disease. Aberrant processing of amyloid precursor protein (APP) leads to Aβ pathology, while hyperphosphorylation of tau protein results in the formation of tau tangles, both contributing to synaptic dysfunction and neurodegeneration, as detailed in the Nature review.
While the study offers a promising avenue for treatment, researchers caution that further investigation is needed to determine the applicability of these findings to humans. The team is currently exploring the possibility of developing small-molecule drugs that can selectively activate the SST1 and SST4 receptors, potentially offering a pill-based treatment option.
The discovery comes as scientists continue to refine methods for early detection of Alzheimer’s disease. Recent advances include blood tests capable of predicting the onset of symptoms with increasing accuracy, measuring levels of amyloid beta peptides in plasma, and PET tracers used to visualize amyloid pathology in the brain, as reported by JAMA Network.
